|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's Range||124.88 - 126.84|
|52 Week Range||103.13 - 129.70|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||31.44|
|Earnings Date||Oct 20, 2021|
|Forward Dividend & Yield||1.80 (1.42%)|
|Ex-Dividend Date||Oct 14, 2021|
|1y Target Est||137.05|
Subscribe to Yahoo Finance Plus to view Fair Value for ABTLearn more
In this article, we will take a look at the 10 stocks making moves on financial results. You can skip our detailed analysis of these companies, and go directly to the 5 Stocks Making Moves on Financial Results. Investors are closely watching the third-quarter earnings season, with several big-cap companies releasing their financial results. Tesla, […]
Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. Abbott provided its third-quarter update before the market opened on Wednesday. Here are three things that investors should love about the healthcare-giant's Q3 results.
Abbott Laboratories (ABT), a multinational medical devices and health care company, reported better-than-expected third-quarter results driven by solid COVID-19 related sales, new product approvals, and overall strong demand for all of its offerings. Following the news, shares jumped 3.3% to close at $123.31 on October 20. The company reported adjusted earnings of $1.40 per share, up 42.9% year-over-year, beating consensus estimates of $0.93 per share. Additionally, quarterly sales stood at $10.